基本统计
| CIK | 1268659 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Prolor Biotech, Inc.
SEC Filings (Chronological Order)
本页提供了美国证券交易委员会（SEC）备案的完整、按时间顺序排列的列表，不包括我们在其他地方提供的所有权备案。
| September 26, 2013 |
15-12B 1 d606242d1512b.htm FORM 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-34676 PROLOR BIOTECH, INC. (Exac |
|
| September 9, 2013 |
AGREEMENT TO FILE JOINT SCHEDULE 13D EX-99.1 2 v354622ex99-1.htm EX-99.1 Exhibit 99.1 AGREEMENT TO FILE JOINT SCHEDULE 13D Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of PROLOR Bi |
|
| September 9, 2013 |
PBTH / Prolor Biotech, Inc. / FROST PHILLIP MD ET AL - SC 13D/A Activist Investment SC 13D/A 1 v354622sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* PROLOR BIOTECH, INC. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 607826104 (CUSIP Number) Steven D. Rubin, Esq. c/o OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Te |
|
| September 6, 2013 |
As filed with the Securities and Exchange Commission on September 6, 2013 Registration No. |
|
| September 6, 2013 |
POS AM 1 v354534posam.htm POS AM As filed with the Securities and Exchange Commission on September 6, 2013 Registration No. 333-180619 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROLOR BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 20-0854033 |
|
| September 6, 2013 |
As filed with the Securities and Exchange Commission on September 6, 2013 Registration No. |
|
| August 30, 2013 |
AMENDED AND RESTATED ARTICLES OF INCORPORATION PROLOR BIOTECH, INC., a Nevada corporation EX-3.1 2 v354048ex3-1.htm EX-3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF PROLOR BIOTECH, INC., a Nevada corporation The original Articles of Incorporation of PROLOR Biotech, Inc., a Nevada corporation (the “Corporation”), were filed with the Nevada Secretary of State on August 22, 2003, under the Corporation’s original name, “LDG, Inc.” (the “Original Articles”). The Original Articles we |
|
| August 30, 2013 |
AMENDED AND RESTATED CODE OF BYLAWS PROLOR BIOTECH, INC. ARTICLE I AMENDED AND RESTATED CODE OF BYLAWS OF PROLOR BIOTECH, INC. ARTICLE I IDENTIFICATION Section 1.01. Name. The name of the corporation is PROLOR Biotech, Inc. Section 1.02. Registered Office and Registered Agent. The address of the registered office of the corporation is 300 South Fourth Street, Suite 1700, Las Vegas, Nevada 89101; and the name of the registered agent at this address is Lionel Sawye |
|
| August 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2013 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-34676 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 9, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34676 PROLOR BIOTECH, INC. |
|
| July 24, 2013 |
DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 16, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2 ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: þ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission only (as permitted by Rule |
|
| July 10, 2013 |
PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 3, 2013 |
PROLOR BIOTECH TO PRESENT POSITIVE RESULTS FROM PRECLINICAL STUDIES Of LONG-ACTING CLOTTING FACTOR Vlla-CTP AT ISTH 2013 -New Data Show a Simple Subcutaneous Injection of Factor Vlla-CTP Could Potentially Replace Current Therapies Administered Via Infusion- Amsterdam, Netherlands and Nes-Ziona, Israel – July 3, 2013 – PROLOR Biotech, Inc. |
|
| July 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2013 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-34676 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| July 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2013 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-34676 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| July 3, 2013 |
PROLOR BIOTECH TO PRESENT POSITIVE RESULTS FROM PRECLINICAL STUDIES Of LONG-ACTING CLOTTING FACTOR Vlla-CTP AT ISTH 2013 -New Data Show a Simple Subcutaneous Injection of Factor Vlla-CTP Could Potentially Replace Current Therapies Administered Via Infusion- Amsterdam, Netherlands and Nes-Ziona, Israel – July 3, 2013 – PROLOR Biotech, Inc. |
|
| July 3, 2013 |
MOD - 5014 - A Long Acting FVIIa NYSE Amex: PBTH Non - Confidential MOD - 5014 - A Long Acting FVIIa NYSE Amex: PBTH Non - Confidential Presentation includes discussion of the following off - label use of a drug or medical device: N/A Disclosures of: GILI HART Employment PROLOR BIOTECH Research support No conflict of interest to disclose Scientific advisory board No conflict of interest to disclose Consultancy No conflict of interest to disclose Speakers bureau No |
|
| July 3, 2013 |
MOD - 5014 - A Long Acting FVIIa NYSE Amex: PBTH Non - Confidential MOD - 5014 - A Long Acting FVIIa NYSE Amex: PBTH Non - Confidential Presentation includes discussion of the following off - label use of a drug or medical device: N/A Disclosures of: GILI HART Employment PROLOR BIOTECH Research support No conflict of interest to disclose Scientific advisory board No conflict of interest to disclose Consultancy No conflict of interest to disclose Speakers bureau No |
|
| June 28, 2013 |
PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 17, 2013 |
EX-99.1 2 v347771ex99-1.htm EXHIBIT 99.1 Rats Monkeys PROLOR Biotech Inc. is a clinical stage public company developing long acting versions of existing therapeutic proteins, utilizing a technology called CTP. The technology involves fusion of the C terminus peptide of β-hCG to the target protein. CTP enabled the production of a long-acting hGH (MOD-4023), which obviates the need for the numerous |
|
| June 17, 2013 |
Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2013 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-34676 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 12, 2013 |
As filed with the Securities and Exchange Commission on June 12, 2013 Registration No. |
|
| June 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2013 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-34676 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| June 4, 2013 |
PROLOR BIOTECH initiates PIVOTAL phase III trial of ITS Longer-Acting Version of human growth hormone Nes-Ziona, Israel– June 4, 2013 – PROLOR Biotech, Inc. |
|
| June 4, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2013 PROLOR BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 001-34676 20-0854033 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 4, 2013 |
PROLOR BIOTECH initiates PIVOTAL phase III trial of ITS Longer-Acting Version of human growth hormone Nes-Ziona, Israel– June 4, 2013 – PROLOR Biotech, Inc. |
|
| June 4, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2013 PROLOR BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 001-34676 20-0854033 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 10, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-52691 PROLOR BIOTECH, INC. |
|
| April 29, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2013 PROLOR BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-52691 20-0854033 (State or other jurisdiction of incorporation) (Commission File |
|
| April 29, 2013 |
Execution Version AGREEMENT AND PLAN OF MERGER BY AND AMONG OPKO HEALTH, INC., POM ACQUISITION, INC., AND PROLOR BIOTECH, INC. Dated as of April 23, 2013 TABLE OF CONTENTS Page Article 1 TRANSACTIONS AND TERMS OF MERGER 2 1.1 Merger 2 1.2 Time and Place of Closing 2 1.3 Effective Time 2 1.4 Charter and Bylaws. 3 1.5 Directors and Officers 3 1.6 Conversion of Shares 3 1.7 Anti-Dilution Provisions 4 |
|
| April 29, 2013 |
EX-2.1 2 v342763ex2-1.htm EXHIBIT 2.1 Execution Version AGREEMENT AND PLAN OF MERGER BY AND AMONG OPKO HEALTH, INC., POM ACQUISITION, INC., AND PROLOR BIOTECH, INC. Dated as of April 23, 2013 TABLE OF CONTENTS Page Article 1 TRANSACTIONS AND TERMS OF MERGER 2 1.1 Merger 2 1.2 Time and Place of Closing 2 1.3 Effective Time 2 1.4 Charter and Bylaws. 3 1.5 Directors and Officers 3 1.6 Conversion of S |
|
| April 29, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2013 PROLOR BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-52691 20-0854033 (State or other jurisdiction of incorporation) (Commission File |
|
| April 25, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| April 25, 2013 |
DEF 14A 1 v342038def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o P |
|
| April 24, 2013 |
EX-99.1 Exhibit 99.1 OPKO HEALTH TO ACQUIRE PROLOR BIOTECH —Acquisition Adds Promising Late Stage Product hGH-CTP Targeting Growth Hormone Deficiency and Preclinical Products Targeting Hemophilia, Obesity & Diabetes— —Complementary Drug Development Technologies Strengthen OPKO’s Innovation Leadership— —PROLOR to Host Conference Call at 8:30 A.M. EDT Thursday, April 25 to Discuss Transaction— Miami |
|
| April 24, 2013 |
DEFA14A 1 v3423158k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2013 PROLOR BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-52691 20-0854033 (State or other jurisdiction of |
|
| April 24, 2013 |
Financial Statements and Exhibits, Other Events 8-K 1 v3423158k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2013 PROLOR BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 000-52691 20-0854033 (State or other jurisdiction of inc |
|
| April 24, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2013 OPKO Health, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33528 75-2402409 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 24, 2013 |
OPKO HEALTH TO ACQUIRE PROLOR BIOTECH —Acquisition Adds Promising Late Stage Product hGH-CTP Targeting Growth Hormone Deficiency and Preclinical Products Targeting Hemophilia, Obesity & Diabetes— —Complementary Drug Development Technologies Strengthen OPKO’s Innovation Leadership— —PROLOR to Host Conference Call at 8:30 A. |
|
| April 24, 2013 |
EX-99.1 2 v342315ex99-1.htm EXHIBIT 99.1 OPKO HEALTH TO ACQUIRE PROLOR BIOTECH —Acquisition Adds Promising Late Stage Product hGH-CTP Targeting Growth Hormone Deficiency and Preclinical Products Targeting Hemophilia, Obesity & Diabetes— —Complementary Drug Development Technologies Strengthen OPKO’s Innovation Leadership— —PROLOR to Host Conference Call at 8:30 A.M. EDT Thursday, April 25 to Discus |
|
| April 24, 2013 |
Merger Overview April 25 2013 NYSE: OPK NYSE Mkt : PBTH Merger Overview April 25 2013 NYSE: OPK NYSE Mkt : PBTH Safe Harbor Statement This presentation contains " forward - looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other |
|
| April 24, 2013 |
Merger Overview April 25 2013 NYSE: OPK NYSE Mkt : PBTH Merger Overview April 25 2013 NYSE: OPK NYSE Mkt : PBTH Safe Harbor Statement This presentation contains " forward - looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other |
|
| February 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2013 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-52691 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 6, 2013 | ||
| February 6, 2013 |
PROLOR BIOTECH TO PRESENT NEW PRECLINICAL DATA ON ITS LONG-ACTING CLOTTING FACTOR Vlla AT LEADING EUROPEAN SCIENTIFIC CONFERENCE -New Data Demonstrate Potential for Long-Acting Subcutaneous Administration, Potentially Allowing Hemophilia Patients to Self-Administer Factor Vlla-CTP at Home Prophylactically- Warsaw, Poland and Nes-Ziona, Israel – February 6, 2013 – PROLOR Biotech, Inc. |
|
| February 6, 2013 |
Regulation FD Disclosure - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2013 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-52691 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| December 12, 2012 |
Corporate Presentation Dec 2012 NYSE Mkt : PBTH Corporate Presentation Dec 2012 NYSE Mkt : PBTH Safe Harbor Statement This presentation contains forward - looking statements, including statements regarding the results of current studies and pre - clinical experiments of PROLOR’s long - acting protein programs and are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995 . |
|
| December 12, 2012 |
Regulation FD Disclosure - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2012 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-52691 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 7, 2012 |
Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2012 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-52691 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| December 7, 2012 |
PROLOR BIOTECH TO PRESENT PRECLINICAL DATA ON ITS LONG-ACTING CLOTTING FACTOR Vlla AT 2012 ASH ANNUAL MEETING Atlanta, GA, USA and Nes-Ziona, Israel – December 7, 2012 – PROLOR Biotech, Inc. |
|
| December 7, 2012 |
F F Factor VIIa - CTP, a Novel Long - Acting Coagulation Factor, Displays a Prolonged Hemostatic Effect and Augmented Pharmacokinetics and Pharmacodynamics Following IV and SC Administration in Hemophilic Animal Models F C Introduction : Prolor Biotech Inc . |
|
| November 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2012 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-52691 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2012 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-52691 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 16, 2012 |
PBTH / Prolor Biotech, Inc. / FROST PHILLIP MD ET AL - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* PROLOR BIOTECH, INC. (Name of Issuer) common stock, par value $0.00001 per share (Title of Class of Securities) 607826104 (CUSIP Number) Shai Novik 7 Golda Meir Street Weizmann Science Park Nes-Ziona, Israel 74140 Telephone: (866) 644-7811 (Name, address and telepho |
|
| May 14, 2012 |
EX-99.1 4 v312938ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PROLOR BIOTECH Announces PROPOSED Public Offering of Common Stock Nes-Ziona, Israel – May 10, 2012 – PROLOR Biotech, Inc. (NYSE Amex: PBTH; TASE: PBTH) today announced that it intends, subject to market conditions, to offer and sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as the sole bo |
|
| May 14, 2012 |
6,500,000 PROLOR Biotech, Inc. UNDERWRITING AGREEMENT Exhibit 1.1 6,500,000 PROLOR Biotech, Inc. UNDERWRITING AGREEMENT May 11, 2012 JEFFERIES & COMPANY, INC. As Representative of the several Underwriters c/o JEFFERIES & COMPANY, INC. 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. PROLOR Biotech, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the |
|
| May 14, 2012 |
Entry into a Material Definitive Agreement, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2012 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-52691 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 14, 2012 |
Exhibit 99.2 PROLOR BIOTECH Announces PRICING OF Public Offering of Common Stock Nes-Ziona, Israel – May 11, 2012 – PROLOR Biotech, Inc. (NYSE Amex: PBTH; TASE: PBTH), today announced the pricing of its previously announced underwritten public offering of 6.5 million shares of its common stock at a price to the public of $5.00 per share. The gross proceeds to PROLOR from this offering are expected |
|
| May 11, 2012 |
The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| May 11, 2012 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-180619 PROSPECTUS SUPPLEMENT (To prospectus dated April 26, 2012) 6,500,000 Shares Common Stock We are offering 6,500,000 shares of our common stock, par value $0.00001 per share. Our common stock is listed on the NYSE Amex under the symbol “PBTH”. On May 10, 2012, the last reported sale price of our common stock on the NYSE Amex was $5.69 per |
|
| May 10, 2012 |
PROLOR BIOTECH LTD. NON COMPETE AGREEMENT PROLOR BIOTECH LTD. NON COMPETE AGREEMENT This Non Compete Agreement (the "Agreement") is entered into by and between Prolor Biotech Ltd., an Israeli company (together with any current and future subsidiaries, affiliates, successors or assigns, the "Company"), and Fuad Fares ("Consultant"). In consideration of Consultant's employment with the Company and the receipt of consideration previously pai |
|
| May 10, 2012 |
Entry into a Material Definitive Agreement - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2012 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-52691 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 10, 2012 | ||
| May 10, 2012 |
PROLOR BIOTECH LTD. NON COMPETE AGREEMENT PROLOR BIOTECH LTD. NON COMPETE AGREEMENT This Non Compete Agreement (the "Agreement") is entered into by and between Prolor Biotech Ltd., an Israeli company (together with any current and future subsidiaries, affiliates, successors or assigns, the "Company"), and Abraham Havron ("Consultant"). In consideration of Consultant's employment with the Company and the receipt of consideration previously |
|
| May 10, 2012 | ||
| May 7, 2012 |
May 2012 1 Safe Harbor Statement This presentation contains forward-looking statements, including statements regarding the results of current studies and pre-clinical experiments of PROLOR’s long-acting protein programs and are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. |
|
| May 7, 2012 |
PROLOR BIOTECH ANNOUNCES TOP-LINE RESULTS FROM FOUR-MONTH TREATMENT EXTENSION OF ITS LONG-ACTING HUMAN GROWTH HORMONE PHASE II TRIAL —Study of hGH-CTP Given Once-Weekly to Growth Hormone Deficient Adults for Four Months Reaffirms Prior Phase II Findings Showing a Single Weekly Injection of hGH-CTP has Potential to Replace Seven Daily Injections of Commercial hGH— —Data to be Presented Tomorrow at the Joint 15th International Congress of Endocrinology and 14th European Congress of Endocrinology in Florence, Italy— Nes-Ziona, Israel – May 7, 2012 – PROLOR Biotech, Inc. |
|
| May 7, 2012 |
Regulation FD Disclosure - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2012 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-52691 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 24, 2012 |
VintageFilings,LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 24, 2012 |
- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| April 20, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2012 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-52691 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 20, 2012 |
PROLOR Biotech Receives Letter from NYSE Amex Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders Nes-Ziona, Israel – April 20, 2012 – PROLOR Biotech, Inc. |
|
| April 19, 2012 |
Long Acting Reversible PEGylated Oxyntomodulin - MOD - 6030 Apr 2012 5th Diabetes Drug Discovery & Development Conference Safe Harbor Statement This presentation contains forward - looking statements, including statements regarding the results of current studies and pre - clinical experiments and the effectiveness of PROLOR’s long - acting protein programs and are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995 . |
|
| April 19, 2012 |
Regulation FD Disclosure - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2012 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-52691 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 6, 2012 |
As filed with the Securities and Exchange Commission on April 6, 2012 Registration No. |
|
| February 24, 2012 |
Abstract Preview Abstract nr. - FVIIa-CTP and FIX-CTP, a novel long-acting coagulation factors with prolonged haemostatic effect and improved recovery in FVIII-/- and FIX-/- mice Background: Prolor Biotech Inc. develops biobetter long acting versions of Factor VIIa and Factor IX utilizing a technology called CTP which involves fusion of the C terminus peptide of beta hCG to a target protein. The t |
|
| February 24, 2012 |
Regulation FD Disclosure - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2012 PROLOR BIOTECH, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-52691 20-0854033 (State or Other Jurisdiction of Incorporation) (Commission Fi |
